SEARCH

SEARCH BY CITATION

References

  • 1
    McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S. Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 1998; 219: 10919.
  • 2
    Schlondorff J, Blobel CP. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 1999; 112: 360317.
  • 3
    Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 1999; 154: 1489501.
  • 4
    Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, Murphy G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473: 2759.
  • 5
    Millichip MI, Dallas DJ, Wu E, Dale S, McKie N. The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998; 245: 5948.
  • 6
    Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P, Blobel CP. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 1999; 274: 353140.
  • 7
    Howard L, Zheng Y, Horrocks M, Maciewicz RA, Blobel C. Catalytic activity of ADAM28. FEBS Letters 2001; 498: 826.
  • 8
    Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun 2004; 315: 7984.
  • 9
    Rosendahl MS, Ko SC, Long DL, Brewer MT, Rosenzweig B, Hedl E, Anderson L, Pyle SM, Moreland J, Meyers MA, Kohno T, Lyons D, et al. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 1997; 272: 2458893.
  • 10
    Fourie AM, Coles F, Moreno V, Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003; 278: 3046977.
  • 11
    Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8: 3540.
  • 12
    Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998; 17: 726072.
  • 13
    Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, Shiomi T, Yoshida K, Nakada M, Ohuchi E, Okada Y. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004; 165: 174353.
  • 14
    Goodman GE. Prevention of lung cancer. Crit Rev Oncol Hematol 2000; 33: 18797.
  • 15
    Carney DN. New agents in the management of advanced non-small cell lung cancer. Semin Oncol 1998; 25: 838.
  • 16
    Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 2002; 35: 24955.
  • 17
    Bodey B, Bodey BJr, Groger AM, Siegel SE, Kaiser HE. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001; 15: 17580.
  • 18
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 105968.
  • 19
    Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 17107.
  • 20
    Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997; 57: 205560.
  • 21
    Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ, Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 3944.
  • 22
    d'Ortho MP, Stanton H, Butler M, Atkinson SJ, Murphy G, Hembry RM. MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Lett 1998; 421: 15964.
  • 23
    Wu E, Croucher PI, McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 1997; 235: 43742.
  • 24
    Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE. ADAM (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002; 185: 33240.
  • 25
    Roberts CM, Tani PH, Bridges LC, Laszik Z, Bowditch RD. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem 1999; 274: 292519.
  • 26
    Haidl ID, Huber G, Eichmann K. An ADAM family member with expression in thymic epithelial cells and related tissues. Gene 2002; 283: 16370.
  • 27
    Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem 1998; 273: 169937.
  • 28
    Loechel F, Wewer UM. Activation of ADAM 12 protease by copper. FEBS Lett 2001; 506: 658.
  • 29
    Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275: 3917481.
  • 30
    Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 1516.
  • 31
    Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002; 62: 35307.
  • 32
    Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 18538.
  • 33
    Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001; 276: 2543846.
  • 34
    Bridges LC, Tani PH, Hanson KR, Roberts CM, Judkins MB, Bowditch RD. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin α 4β 1. J Biol Chem 2002; 277: 378492.
  • 35
    Bredin CG, Sundqvist KG, Hauzenberger D, Klominek J. Integrin dependent migration of lung cancer cells to extracellular matrix components. Eur Respir J 1998; 11: 4007.
  • 36
    Retzios AD, Markland FSJr. A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: effects on various components of the human blood coagulation and fibrinolysis systems. Thromb Res 1988; 52: 54152.
  • 37
    Kamiguti AS, Slupsky JR, Zuzel M, Hay CR. Properties of fibrinogen cleaved by Jararhagin, a metalloproteinase from the venom of Bothrops jararaca. Thromb Haemost 1994; 72: 2449.
  • 38
    Jeon OH, Kim DS. Cloning, expression, and characterization of a cDNA encoding snake venom metalloprotease. Biochem Mol Biol Int 1999; 47: 41725.
  • 39
    Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-α in cancer. Curr Opin Immunol 1998; 10: 57380.
  • 40
    Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K, Mizuno H, Ishiguro S, Kiyohara T, Miyazaki Y, Taniguchi N, Higashiyama S, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002; 98: 50513.